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1. Introduction 
1.1 Purpose of the introduction 
The purpose of the introduction is to bring the reader into the concept of 
inflammatory bowel disease associated anaemia and its management, with emphasis 
on problems related to deterioration of oxidative stress during iron therapy.   
1.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a group of disorders of the gastrointestinal tract 
characterised by intestinal inflammation and a chronic relapsing course. IBD has 
traditionally been categorised as either ulcerative colitis (UC) or Crohn’s disease 
(CD) on the basis of clinical, radiological, endoscopic and histological criteria. About 
10 % of colitis cases show overlapping features of the two major forms and are called 
intermediate colitis.  
Although the aetiology of IBD remains to be defined, recent experimental and 
clinical studies suggest that the initiation and pathogenesis of these diseases are 
multi-factorial, involving interactions among genetic, environmental and immune 
factors (1). 
1.2.1 Epidemiology 
Inflammatory bowel disease is not evenly distributed world-wide. There is a clear 
tendency to a higher incidence in developed countries compared with less developed 
countries (2). North America, the United Kingdom and Scandinavia have the highest 
rates (2). In Norway, the incidence of UC and CD was reported to be 13.6 per 
100 000 and 5.8 per 100 000, respectively (3; 4). UC and CD are most commonly 
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diagnosed in late adolescence and early adulthood, but the diagnosis may occur at all 
ages.  
1.2.2 Pathology and clinical presentation 
UC is a mucosal disease that usually involves the rectum and extends proximally to 
involve all or part of the colon. Proximal spread occurs in continuity without areas of 
uninvolved mucosa. The major symptoms of UC are urgent diarrhoea, rectal 
bleeding, passage of mucus, and crampy abdominal pain. The severity of symptoms 
correlates with the extent of the disease.    
CD can affect any part of the gastrointestinal tract from the mouth to the anus, but 
most commonly affects the small intestine and/or the colon. The inflammation is 
transmural and segmental, with normal areas between patches of diseased intestine. 
Consequences of the inflammation include fistula formation to other loops of bowel, 
the urinary bladder, vagina, or perianal skin, abdominal or perianal abscesses, and 
intestinal strictures. The site and behaviour of the disease influences the clinical 
manifestations. The most common symptoms are diarrhoea, crampy abdominal pain, 
fever, anorexia, and weight loss. 
Extraintestinal manifestations of UC and CD can affect multiple organ systems, such 
as the eyes, skin, and joints, as well as gastrointestinal organs, including the liver and 
gall bladder. 
1.3 Anaemia in inflammatory bowel disease 
1.3.1 Definition of anaemia 
Anaemia is defined as a lowered concentration of blood haemoglobin (Hb). The 
degree of anaemia is often scaled as; mild, haemoglobin 10 g/dL to normal limits; 
moderate, haemoglobin 8 to 10 g/dL; and severe, haemoglobin less than 8 g/dL (5). 
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1.3.2 Prevalence 
One third of patients with UC and CD suffer from anaemia defined as blood 
haemoglobin < 12 g/dL (6; 7). While the understanding of IBD has grown over the 
past decades, the prevalence of IBD associated anaemia has changed only little (8). 
1.3.3 Clinical consequences 
In chronic disease, symptoms of anaemia are often insidious in onset and may seem 
to be less than expected from the haemoglobin concentration. It has been argued that 
patients adapt to low haemoglobin if anaemia develops slowly. However, in the 
recent past it has been suggested that the process of adaptation to chronic anaemia is 
in fact adaptation to a lower quality of life (9). 
Chronic fatigue is a frequent symptom of IBD, and is commonly caused by anaemia 
(8). Dyspnoea and tachycardia are due to peripheral hypoxia, while central hypoxia 
may lead to symptoms such as headache, dizziness, vertigo or tinnitus. Nausea, 
anorexia and weight loss are also associated with anaemia. A common finding is 
menorrhagia and amenorrhoea among women (5). Men may suffer from impotence 
(5). 
1.3.4 Aetiology 
IBD associated anaemia is commonly a combination of iron deficiency anaemia 
(IDA) and anaemia of chronic diseases (ACD). Other mechanisms of anaemia may 
occasionally be relevant. 
Iron deficiency 
Iron deficiency is defined as a reduction in total body iron to an extent that iron stores 
are completely exhausted. Absolute iron deficiency is accompanied by IDA. In latent 
iron deficiency iron stores are empty but anaemia has not yet developed. 
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In man the normal diet should contain 13-18 mg of iron per day of which only 1-2 
mg are absorbed (10; 11). Balance is achieved through daily iron losses from the gut, 
skin and sweat of 1-2 mg (12). In iron-deficient states, absorption may increase to a 
maximum of 2-4 mg (10; 11). Therefore, ongoing losses of ≥ 10 ml of blood (1 ml of 
blood contains 0.5 mg of iron) daily will result in iron deficiency (10). 
Chronic intestinal bleeding in IBD may exceed the amount of iron that can be 
absorbed from the diet, resulting in a negative iron balance (13). Although iron 
absorption in IBD is generally normal, it can occasionally be impaired in extensive 
CD of the duodenum and upper jejunum (14). 
Food aversion and self-reported intolerance are common in IBD and this will affect 
the amount of iron available in the diet (15; 16). Various reports have pointed to 
diminished iron intake in IBD predominantly due to avoidance of iron fortified 
cereals which may be perceived to exacerbate abdominal symptoms (17; 18). 
Anaemia of chronic disease 
Anaemia of chronic disease (ACD) occurs in patients with activation of cell mediated 
immunity, such as infections, immune mediated inflammatory disorders or 
malignancy (19). The cytokines most often implicated in the pathogenesis are tumor 
necrosis factor α (TNF-α), interleukin-1, interleukin 6 and interferons (19). Several 
factors contribute to the development of ACD. 
A hallmark of ACD is disturbances in iron homeostasis, with increased uptake and 
retention of iron within cells of the reticuloendothelial system, and down regulation 
of duodenal iron absorption. This leads to hypoferraemia, limiting iron availability in 
erythroid marrow and subsequent iron deficient erythropoiesis. The term functional 
iron deficiency is applied for situations where there is an inadequate iron supply for 
erythropoiesis despite the fact that the iron stores are sufficiently filled with iron. 
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Cytokines directly affect erythropoiesis by inhibiting the proliferation and 
differentiation of erythroid progenitor cells, and the life span of red cells are 
shortened (19). 
Erythropoietin, a hormone secreted by the kidney, regulates erythroid proliferation 
centrally. Under normal physiological conditions, erythropoietin concentration is 
inversely related to tissue oxygenation and haemoglobin levels. Serum erythropoietin 
levels in patients with ACD appear to be inadequately low for the degree of anaemia 
(8). However, this does not hold true for all diseases underlying ACD (20), but has 
been shown for UC and CD (6; 21). 
Vitamin B12 and folate deficiency 
Vitamin B12 (cobalamin) and folic acid are vitamins involved in a series of complex 
biochemical reactions. 
Clinical evidence of vitamin B12 deficiency occurs late as body stores have to be 
depleted to less than 10% (8). Vitamin B12 deficiency is most often a consequence of 
terminal ileal disease or resection. Of those patients with ileal resections of > 60 cm, 
almost all malabsorb vitamin B12, and if < 60 cm, about half have vitamin B12 
malabsorption (22). An association with gastric Crohn’s disease has also been 
recognised (23). 
Clinical evidence of folic acid deficiency occurs early as folate stores last only 1-2 
months. Folic acid is absorbed in the duodenum and jejunum and deficiency may 
arise from inadequate intake, malabsorption, or drug interactions (sulfasalazine, 
methotrexate). 
Drug induced anaemia 
Azathioprine and 6-mercaptopurine have a direct myleosuppressive effect. 
Sulfasalazine and 5-aminosalicylic acid have been related to a minor degree of 
hemolysis or aplasia (24-26). 
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Less common causes of anaemia in IBD are autoimmune haemolytic anaemia (27) 
and myelodysplastic syndromes (28). 
1.3.5 Laboratory diagnosis 
Monitoring of IBD patients with complete blood counts is a routine measure and iron 
parameters, vitamin B12 and folic acid must be checked regularly.  
The lower haemoglobin cut off level is about 12.0 g/dL in women and 13.5 g/dL in 
men. One must keep in mind that patients may have habitual haemoglobin levels 
considerably higher than the cut off level, and anaemia may therefore be present even 
with haemoglobin within the normal range. 
Mean cell volume (MCV) and mean cell haemoglobin (MCH) characterise the 
anaemia. Microcytosis and hypochromia indicate red cell iron deficiency with or 
without concomitant ACD. Macrocytosis points to vitamin B12 or folic acid 
deficiency. An increase in MCV without anaemia is seen during azathioprine and 6-
mercaptopurine therapy. MVC and MCH are late markers and abnormalities in these 
parameters suggest longstanding deficiencies. 
The serum ferritin reflects the iron stores. However, ferritin is an acute phase 
reactant, complicating the interpretation of test results. When serum ferritin is less 
than 15 µg/L, iron stores are definitely depleted. A serum ferritin concentration below 
30 µg/L is diagnostic of IDA in a patient with anaemia (29; 30). Serum ferritin 
concentrations above 50 µg/L usually exclude iron deficiency in patients with ACD 
(30). The C-reactive protein (CRP) is generally considered to be the best laboratory 
marker of inflammation, but the degree of elevation that invalidates the serum ferritin 
criteria of iron deficiency has not been accurately defined. A reasonable interim 
guideline to eliminate an influence of inflammation on serum ferritin is a CRP below 
30 mg/L (31; 32). 
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In pure IDA, the serum transferrin concentration, or total iron binding capacity 
(TIBC), is increased, while the transferrin saturation is decreased (<16%). In ACD, 
both serum transferrin and transferrin saturation are decreased. 
Increased serum transferrin receptor (sTfR) is also a useful indicator of iron 
deficiency. The sTfR is usually normal in ACD, and only increased within the 
reference range in the combined state of ACD and iron deficiency (33). The ratio of 
sTfR/log ferritin has been proposed for the identification of patients with ACD and 
iron deficiency (30), but such ratios are often impractical in clinical practise. 
Two new erythroid indices of iron deficient erythropoiesis have been introduced 
recently. The proportion of hypochromic red cells (HYPO) permits earlier detection 
of iron deficient erythropoiesis than the MCV, but it still takes a few weeks to 
become abnormal (31; 34). A more rapid change occurs with the reticulocyte 
haemoglobin content (CHr) that falls within a couple of days (35). These parameters 
can be assayed by only a few models of haematology analysers and availability is 
therefore limited. 
1.3.6 Treatment 
The therapeutic goal is normalisation of haemoglobin levels (8). In anaemic cancer 
patients, improvements in quality of life were detected at haemoglobin levels of up to 
14 g/dL (36). 
Intestinal inflammation must be treated adequately to reduce blood loss and immune 
activation. The treatment for iron deficiency is iron supplementation. Patients who do 
not respond to iron supplementation may benefit of erythropoietin administration. 
The therapeutic algorithm for IBD associated anaemia developed by Gasche et al. is 
shown in Figure 1. In cases of vitamin B12 or folic acid deficiency, appropriate 
substitution is needed. 
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This paragraph focuses on efficacy and tolerability of oral and intravenous iron 
administration in IBD patients. Iron therapy in general and the relation between iron 
and oxidative stress are outlined in paragraphs 1.5 and 1.6  respectively. 
Hb > 12.0 g/dL
Ferritin < 20 µg/l
Hb 10.0-12.0 g/dl
Ferritin < 200 µg/l
Hb < 10.0 g/dl
Transferrin > 2.9 g/l*
Hb < 10.0 g/dl
Transferrin < 2.9 g/l*
Oral iron
30 mg/day
Iron sucrose
200-300 mg/wk
If Hb < 12.0 g/dl
after 4 wks
Iron sucrose
300-600 mg/wk
If Hb increase is
< 2 g/dl after 4 wks
Iron sucrose
300-600 mg/wk
Erythropoietin
150 U/kg, 3 x per wk
 
Figure 1 Adjusting therapy to the degree of anaemia. The place of oral iron therapy is 
mainly prevention of iron deficiency anaemia. In patients with normocytic or microcytic 
anaemia, iron sucrose demonstrates the best efficacy and tolerability. The amount of 
iron needed relates to the degree of anaemia and can be estimated using the 
approximation that an increase of 1 g/dl haemoglobin (Hb) requires about 200 mg of 
intravenous iron. It is recommended that iron therapy is suspended in cases of acute 
infection (for example, abscess) or at transferring saturation > 50%. *Instead of 
transferrin, the soluble transferrin receptor (below 50 nmol/l) or erythropoietin 
concentration (below 100U/l) can be applied. Gut 2004;53:1190-1197. Reproduced with 
permission from the BMJ Publishing Group. 
Oral iron preparations 
Oral iron supplements commonly contain iron in the form of ferrous salts (ferrous 
sulphate, ferrous fumarate and ferrous gluconate). Nausea, abdominal pain, bloating 
and diarrhoea are frequent side-effects in the IBD population leading to poor 
compliance (37). Iron absorption is limited, and treatment for several months is 
necessary to correct IDA. Chronic inflammatory disease may reduce iron absorption. 
Also, oral iron may not be sufficient to compensate ongoing blood loss in IBD 
patients with severe anaemia (7). Because of these limitations oral iron preparations 
are recommended only for the prevention of anaemia (8). However, until recently 
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oral iron supplementation was also recommended for the treatment of anaemia with 
haemoglobin > 10.5 g/dL (37). 
Ferric iron-polymaltose complex and haeme iron polypeptide are available in some 
countries, but experience and evidence for the use of these formulations in the IBD 
population are lacking.  
Intravenous iron preparations 
Parenteral iron formulations are ferric hydroxide carbohydrate complexes (iron 
dextran, iron sucrose, iron gluconate). During the last few years, experience of using 
intravenous (i.v.) iron sucrose in various forms of iron deficiency has evolved (38). 
The efficacy and tolerability of iron sucrose in IBD patients has been tested in several 
studies. 
Using single doses of 200 mg iron sucrose, twice weekly during the first two weeks 
and once weekly thereafter, approximately 75% of patients with UC and CD 
responded to the treatment after eight weeks (21; 39). Response was defined as an 
increase in haemoglobin of ≥ 2.0 g/dL. In another study, 91% of IBD patients 
responded after 12 weeks of iron sucrose treatment (40). No serious adverse events 
were observed when using individual doses of 200 mg iron sucrose (21; 39; 40). 
Transient burning at the site of venipuncture, bitter taste, transient fever and transient 
hypotension were experienced in a few patients (21; 39; 40). 
To date, no data is available on the efficacy and tolerance of other i.v. iron 
formulations in IBD patients.  
Recombinant human erythropoietin 
Supraphysiological doses of erythropoietin can overcome the inhibition of 
erythropoiesis in ACD (41). IBD patients not responding to iron sucrose alone benefit 
from combined erythropoietin treatment (21; 39). For the reason of costs, 
erythropoietin should be reserved for patients who are resistant to i.v. iron therapy 
(37). In patients with severe anaemia, low plasma erythropoietin (below 100 U/L), 
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sTfR (below 50 nmol/L or 2.7 mg/L) or transferrin levels (below 2.9 g/L) indicated 
resistance to iron sucrose (42). Transferrin of 2.9 g/L is equivalent to TIBC of 73 
µmol/L. 
1.4 Basic aspects of iron metabolism 
All mammalian cells require iron for a wide range of vital biologic processes. Iron is 
centrally involved in oxygen transport by haemoglobin and myoglobin, in electron 
transport during mitochondrial respiration, and in DNA synthesis. However, iron is 
also a potentially toxic substance. The shift back and forth between its two oxidation 
states – ferrous (Fe2+) and ferric (Fe3+) – via single electron transfer reactions is the 
property that makes iron such an essential component of the cytochromes in the 
respiratory chain. This redox property also contributes to its potential toxicity. Redox 
cycling between ferrous and ferric iron can promote the generation of highly reactive 
oxygen species, which can damage lipids, proteins and nucleic acids. Normal iron 
homeostasis allows cells to benefit from the usefulness of iron while avoiding its 
deleterious effects. 
There is no physiologic pathway for excretion of iron. Iron losses occur primarily 
through bleeding and sloughing of mucosal and skin cells. To maintain iron balance, 
intestinal iron absorption is meticulously controlled. Normal adults have 
approximately 4000 mg of total body iron, of which about 3000 mg is found in 
haemoglobin in erythrocytes and their precursors, and 800-1200 mg as storage iron. 
Small amounts of iron also occur in myoglobin and cytochrome enzymes. Only 1-2 
mg of iron enters and leaves the body on a daily basis.  
1.4.1 Iron absorption, transport and storage 
Dietary iron consists of two components, haeme iron (present in meat, fish and 
poultry) and non-haeme iron or inorganic iron (in vegetables, cereals etc.). Haeme 
iron and non-haeme iron are absorbed through distinct pathways (43). 
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Non-haeme iron is transported into the enterocytes in the ferrous (Fe2+) form, and 
most iron absorption takes place in the proximal duodenum, near the gastric outlet. 
Luminal factors strongly influence iron absorption. The gastric acid helps to keep 
iron in the more soluble ferrous form (Fe2+). At the neutral pH of the duodenum, 
ferrous iron is rapidly oxidised to ferric iron (Fe3+), which precipitates into poorly 
absorbed iron hydroxide and iron oxide polymers. Ascorbic acid potentiates iron 
absorption by stabilising the reduced ion (44). In contrast, compounds that bind iron 
make it less available for the absorptive mechanism. Examples of such inhibitors are 
polyphenols (e.g. as in tea and coffee) and phytates (e.g. as in wheat bran, oat, rice 
and maize). 
The first step in iron absorption is transfer across the apical (luminal) membrane of 
the enterocyte. First, ferric iron is reduced to ferrous iron by a brush border 
ferrireductase (DCYTB). Transfer of ferrous iron is then carried out by divalent metal 
transporter 1 (DMT1), a transmembrane protein that functions as a general transporter 
of divalent metals. Once inside the enterocyte, iron has two possible fates. Some 
remains stored within the cell; that iron is ultimately lost from the body at the end of 
the enterocyte lifespan. The remainder is transferred across the basolateral surface 
through ferroportin, a transmembrane protein similar to DMT1. A ferroxidase, 
hephaestin, acts in some way to facilitate basolateral iron transport (45). Basolateral 
plasma transfer is increased in iron deficiency and decreased when body iron is 
plentiful. 
Proteolytic digestion of myoglobin and haemoglobin results in the release of haeme 
(Fe2+-protoporphyrin IX), which is maintained in a soluble form by globin 
degradation products so that it remains available for absorption. Intact haeme is 
transported across the brush border membrane by an unknown mechanism. Inside the 
enterocyte iron is released from the porphyrin ring, and then further processed as 
inorganic iron. Haeme iron from meat is readily absorbed, regardless of other dietary 
components. Up to 30% may be available for absorption (46). On the other hand, 
purified haeme forms large insoluble polymers and are poorly absorbed (47).  
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Iron circulates bound to transferrin, a very abundant plasma protein that binds two 
iron atoms avidly with a dissociation constant of approximately 1022 at physiologic 
pH (48). Transferrin keeps ferric iron soluble and prevents iron from reacting with 
other molecules by attenuating its redox activity. It aids in delivery of iron to cells by 
binding to a specific cell-surface transferrin receptor (TFR1). TFR1 is present in low 
abundance in most if not all mammalian cell types, but is expressed at high levels by 
cell types with large needs for iron, such as developing erythroid precursors. 
In general, two cell types are considered important for storage of iron that is not 
needed for immediate use. Macrophages recover iron from effete erythrocytes. They 
also internalise iron from intravenously administered iron sucrose and iron dextran. 
Hepatocytes acquire both transferrin bound and non-transferrin bound iron from 
plasma. Both the macrophages and the hepatocytes have large capacity for iron 
storage. 
At a molecular level, iron storage occurs primarily in the protein ferritin. It consists of 
24 subunits that sequester iron hydroxide phosphates in a central core. Iron release 
occurs when intracellular pools become depleted. Degradation of ferritin leads to the 
formation of hemosiderin, a non-homogeneous conglomerate of iron, protein and 
membrane breakdown products. 
Measurable changes in intestinal iron absorption and tissue iron distribution are found 
in situations of abnormal iron availability (iron overload or deficiency), accelerated 
erythropoiesis, hypoxia and inflammation. Situations that require decreased iron 
availability are associated with interruption of intestinal absorption and retention of 
iron by macrophages. In contrast, situations requiring increased iron availability are 
associated with increased intestinal absorption and enhanced macrophage iron 
release. Hepcidin, a 25-amino-acid peptide secreted into the plasma from the 
hepatocytes, is probably a key regulator of intestinal iron absorption and also of 
recycling of iron via macrophages (11). Increased hepcidin expression results in 
reduced iron absorption and iron recycling whereas reduced plasma hepcidin acts to 
increase iron absorption and release of iron through macrophages (11).  
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1.4.2 Iron and erythropoiesis 
Erythropoiesis dominates iron metabolism. About 20-25 mg of iron per day is 
required to support the haemoglobinisation of new erythrocytes (49). Most of it 
comes from recycling of iron already in the body. The primary source is 
macrophages, which phagocytose damaged erythrocytes to scavenge their iron from 
haemoglobin and return it to the circulation. The amount of iron passing through this 
macrophage recycling system every day approximates the amount needed for 
erythropoiesis.  
1.5 Iron therapy 
1.5.1 Oral iron preparations 
In otherwise healthy patients, oral iron should be given preference over parenteral 
iron as the initial approach to treatment of iron deficiency.  
Oral iron supplements are commonly in the form of ferrous salts. These are ionic 
compounds composed of the metal iron (cation) and an acid (anion), so that the 
product is neutral (without a net charge). The most common are ferrous sulphate 
(FeSO47H2O), ferrous fumarate (FeC4H2O4) and ferrous gluconate (Fe(C6H11O7)2).  
Ingested ferrous salts are solubilised and ionised by the gastric acid, and the iron is 
absorbed by the same mechanisms as dietary inorganic iron (outlined in paragraph 
1.4.1). However, the tight control of dietary iron absorption seems to be partly out of 
control after pharmacological doses of ferrous salts. With increasing doses, the 
absolute amounts of iron absorbed increase (50; 51).  
Standard iron replacement therapy for adults is 2-3 mg elemental iron/kg body weight 
in three divided doses. Reticulocytosis may be observed as early as 4 days after start 
of treatment and will reach a maximum at 7-10 days. An increase in the haemoglobin 
concentration will follow. Therapy needs to continue for 2-3 months after correction 
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of anaemia in order to replenish the body iron stores (52). The usual cause of failure 
to respond is non-compliance. There is no significant difference in efficacy (53) or 
side-effects (54) between different ferrous compounds when the same amount of 
elemental iron is administered. 
The major difficulty with oral iron is the nausea, vomiting and epigastric discomfort 
that occurs within an hour or two of ingestion. These symptoms vary in proportion to 
the concentration of ionisable iron in the upper gastrointestinal tract and can be 
reduced by taking the iron supplement with food. However, administration with food 
decreases bioavailability. Many patients also complain of bloating, constipation or 
diarrhoea, but these lower gastrointestinal side-effects appear not to be dose related 
(31). Enteric coated ferrous formulations are promoted on the basis of reduced side-
effects, but any reduction in symptoms is invariably due to a parallel decrease in iron 
absorption (8; 31). 
Ferric iron-polymaltose complex and haeme iron polypeptide are also available in 
some countries. Ferric iron-polymaltose complex is a ferric (Fe3+) hydroxide 
carbohydrate complex similar to the parenteral iron formulations. Two smaller 
studies demonstrated that iron-polymaltose complex was as efficient as ferrous 
sulphate in correcting blood haemoglobin levels in iron deficiency anaemia, but iron-
polymaltose complex did not increase serum ferritin to the same extent as ferrous 
sulphate (55; 56). Haeme iron polypeptide is produced by hydrolysis of bovine 
haemoglobin. The extraction technique leaves peptides from the globin subunits 
covalently bound to the haeme ring, improving solubility (57). The product is thought 
to have improved bioavailibility and promises lower side-effects (57). Larger series 
have not yet been treated with any of these compounds. 
1.5.2 Intravenous iron preparations 
Indications for intravenous iron therapy are given in Table 1. 
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Table 1. Indications for intravenous iron therapy 
 
High iron needs 
 
 
 
 
Need for fast correction of anaemia 
 
 
Failure of oral iron therapy 
 
Significant gastrointestinal bleeding 
Erythropoietin therapy 
Menorrhagia 
Pregnancy 
 
Post-partum anaemia 
Post-operative anaemia 
 
Intolerance 
Poor compliance 
Malabsorption 
  
Direct administration of iron into the circulation requires formulations that prevent 
the cellular toxicity of iron salts (58). I.v. iron agents consist of a core of non-ionic 
ferric hydroxide molecules surrounded by a shell of carbohydrate. They differ from 
each other by the size of the core and the identity and the density of the surrounding 
carbohydrate. 
After i.v. administration, ferric hydroxide carbohydrate complexes are taken up by 
the reticuloendothelial system. Within macrophages, iron is released from the iron-
carbohydrate compound and either stored as ferritin or released into the circulation 
where it combines with transferrin for transport to the bone marrow. A small fraction, 
however, likely bypasses the intracellular steps and donates iron directly to transferrin 
in plasma (59). Three different products are currently available.  
Iron dextran 
Iron dextran is a stable parenteral iron product with molecular weight of 100-300 kD. 
The plasma half-life is 30 to 60 hours (60). Stability allows administration of high 
single doses of 500-1000 mg iron. The reticulocyte count can increase within 7 days 
and haemoglobin responses occur within 1-2 weeks of iron dextran administration 
(61). 
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Anaphylactic reactions to the dextran moiety are seen in up to 1.7% of infusions (62). 
The risk of a life-threatening/serious acute reaction is on the order of 0.7% (62). The 
reaction typically occurs during the first several minutes of administration. A test 
dose should be given to all new patients started on iron dextran, and in patients 
receiving repeat doses after an interval of non-treatment (61; 63). In addition, special 
caution should be exercised in patients with multiple drug allergies/intolerance (63). 
Delayed reactions of hypotension, arthralgias, myalgias, malaise, nausea, and 
vomiting occurred in about 10% of patients after high doses (61; 64; 65). 
Iron dextran may be administered intravenously by slow injection or infusion. It may 
also be administered by the intramuscular route. However, pain on injection, staining 
of the skin, unpredictable delivery, and absorption of iron make the intramuscular 
route undesirable (61). 
One form of iron dextran is currently available in some European countries, and 
marketed under the name of Cosmofer®. Iron dextran Cosmofer® is identical to iron 
dextran InFed® available in the United States. 
Iron sucrose 
Iron sucrose has a molecular weight of 43 kD. The plasma half life is 5-6 hours (66). 
Iron sucrose, like iron gluconate, is more readily available for erythropoiesis than 
iron dextran (38). Increase in haemoglobin concentration is noted after one week of 
iron sucrose administration (67). 
There is no risk of anaphylactic reactions, and a test dose is not required. Iron sucrose 
must be administered intravenously by slow injection or infusion. Single doses of up 
to 300 mg iron sucrose are safe (68). The maximal recommended dosage is 600 
mg/week, but this amount exceeds the physiological needs of the erythropoiesis. If 
the infusion speed is too fast or the single total iron dose is too high transient 
hypotension, tachycardia, dyspnoea, nausea and lower back pain can occur (8; 68).  
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Iron sucrose is available in Europe, North America, and most countries world-wide as 
Venofer®.   
Iron gluconate 
Ferric gluconate has a molecular weight of 38 kD, and a plasma half-life of 1 h (58; 
61; 69). 
Iron gluconate has not been associated with anaphylactic reactions, and a test dose is 
not required. A standard dose of 125 mg may be administered intravenously by slow 
injection or infusion. Doses of 250 mg i.v. have been reported to be well tolerated 
(70). High infusion speed or high single iron doses may cause nausea, hypotension, 
tachycardia and dyspnoea (8). The use of iron gluconate for iron deficiency in 
patients on dialysis has been found to be safe and superior to iron dextran (71; 72).  
Ferric gluconate is available in several European countries and the United States as 
Ferrlecit®.   
1.6 Oxidative stress 
Oxidative stress is defined as an absolute or relative increase in reactive oxygen 
species (ROS), and may be caused by increased production of ROS, or diminished 
antioxidant defences, or often a combination of these. Oxidative stress may lead to 
oxidative damage of biological molecules and is believed to constitute a major tissue-
destructive mechanism (73). 
Under normal conditions, about 2% of the oxygen we breathe is used to make ROS, a 
production approximately balanced by the antioxidant system (74). During the 
inflammatory response, activated neutrophils and macrophages release large amounts 
of ROS. Although ROS generation by phagocytes is essential for an effective defence 
against invading microbes, its sustained overproduction during chronic inflammation 
may cause extensive tissue destruction (75). 
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1.6.1 Reactive oxygen species 
Reduction-oxidation (or redox) reactions involve loss of one or more electrons by one 
molecule (oxidation) and simultaneous gain by another (reduction). A free radical 
(denoted •) is any atom or molecule that contains one or more unpaired electrons, and 
is typically unstable and reactive. 
ROS are intermediates that appear in the stepwise reduction of oxygen to water. 
These include superoxide anion (O2-•), hydrogen peroxide (H2O2) and hydroxyl 
radical (OH•). Occasionally, the term is expanded to include hypochlorous acid 
(HOCl), peroxynitrite anion (ONOO-), and nitric oxide (NO).  
O2-• and H2O2 are not considered as particular reactive intermediates (76). However, 
in the presence of “free” iron they may react to form the extremely reactive OH• in 
the so-called Haber-Weiss reaction (reaction I + II): 
O2-• + Fe3+ → O2 + Fe2+   (I) 
and 
H2O2 + Fe2+ → Fe3+ + OH- + OH• (II; Fenton reaction) 
OH• is considered to be the most reactive ROS (76). It can attack and damage almost 
every molecule in living cells, including lipids, proteins, and DNA. 
To promote the generation of ROS, iron must be either freely water-soluble or 
weakly bound to small organic ions (77). In plasma and tissues, the concentration of 
such low molecular chelated iron is low due to the tight control of iron homeostasis. 
1.6.2 Oxidative damage 
The overall high reactivity and short half-life of ROS implies that the tissue damage 
they inflict is generally close to the site of generation. 
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Membrane lipids 
The polyunsaturated fatty acids located within the cell membrane lipid bilayer are 
major targets for ROS attack (78). They are particularly effectively attacked by OH•, 
thereby initiating the process of lipid (LH) peroxidation. Once initiated, lipid 
peroxidation propagates as a chain reaction, and a single oxidative event can thus 
affect many lipid molecules.  
LH + OH• → L• + H2O   
L• + O2 → LOO•    
LH + LOO• → L• + LOOH 
The end products of the chain reaction are a variety of lipid hydroperoxides (LOOH), 
which decompose to aldehydes.  
Once initiated, lipid peroxidation is most successfully terminated by lipid soluble 
chain-breaking antioxidants such as vitamin E (79). 
Extensive lipid peroxidation in the cell membrane has a profound effect on its fluidity 
and, as such, on the activity of transmembrane enzymes, transporters, receptors, and 
other membrane proteins (80; 81). As a result, lipid peroxidation causes changes in 
membrane permeability and selectivity, and ultimately leads to alterations in cell 
volume homeostasis and cellular metabolism (82). Some products of peroxide 
decomposition are also cytotoxic (83). 
Frequently used markers of lipid peroxidation are malondialdehyde (MDA), 
tiobarbituric acid-reacting substances (TBARS), lipid hydroperoxides and F2-
isoprostanes. 
Proteins and DNA 
Proteins are the most abundant cell constituents, which make them important ROS 
targets (84). Moreover, a relative minor oxidative modification of a single protein can 
lead to a marked change (in most cases lowering) in its biological activity. Similar to 
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lipid peroxidation, OH• seems to be most effective in inducing oxidative protein 
damage (84). The process of protein oxidation frequently introduces new functional 
groups, such as hydroxyls and carbonyls, which contribute to altered function, 
turnover, and degradation (85).  
Both nuclear and mitochondrial DNA are known targets of ROS attack (86). Many 
types of DNA modification can occur, and may in turn lead to malignant 
transformation or cell death (76). 
1.6.3 Antioxidant defences 
An antioxidant is any substance that considerably delays or inhibits oxidation. 
Roughly, the components of the antioxidant defence system can be categorised into 
non-enzymatic and enzymatic antioxidants. 
Non-enzymatic antioxidants 
Non-enzymatic antioxidant defences are largely extracellular. The binding of free 
metal ions, in particular iron and copper, is an important defence mechanism. Iron 
bound to transferrin and lactoferrin, and copper bound to ceruloplasmin, can not 
catalyse redox reactions (78). Haptoglobin and haemopexin bind free haeme and 
haeme proteins to minimise their ability to participate in redox reactions (78). 
Several dietary compounds with antioxidant properties, which normally originate 
from natural sources, such as fruits and vegetables are considered to be of 
importance. Vitamin E (α-tocopherol) is a lipid soluble chain breaking antioxidant, β-
Carotene is a lipid soluble radical scavenger, while vitamin C (ascorbic acid) is a 
water soluble radical scavenger (78).  
Reduced glutathione, a tripeptide with a reactive sulphydryl group, is an important 
intracellular antioxidant. Apart from being a substrate for the enzyme glutathione 
peroxidase (se below), glutathione serves as a scavenger of several ROS (87). During 
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its antioxidant function, reduced glutathione is converted to its oxidised state, upon 
which it is reduced back again by the enzyme glutathione reductase.  
Antioxidant enzymes 
The most important component of the endogenous defence system against ROS is the 
enzymatic machinery that is found in all cells. The antioxidant enzymes remove key 
ROS in a two-step pathway. Superoxide dismutases (SOD) convert  O2-• to H2O2, 
which is subsequently neutralised to water by catalase or glutathione peroxidase 
(GPO). The enzymes are not consumed by the reaction (78). 
1.6.4 Oxidative stress in anaemia 
The prooxidant-antioxidant balance may be altered in anaemia. Tissue hypoxia is 
accompanied by an absolute increase in ROS production due to changes in cellular 
metabolism, higher flux rates in catecholamine metabolism, and activation of 
leukocytes (88). Also, the antioxidant system is markedly weakened by anaemia. The 
erythrocytes represent a major component of the antioxidant capacity of the blood, 
comprising the antioxidant enzymes SOD and catalase, and the glutathione system.  
1.6.5 Oxidative stress in inflammatory bowel disease 
Pathogenesis 
Oxidative tissue damage constitutes an important pathogenic factor in IBD (89). ROS 
are produced in large amounts by infiltrating leukocytes in the inflamed mucosa.  
Using direct and indirect measurements of lipid peroxidation, increased levels of lipid 
peroxidation products have been consistently found in IBD and are mostly correlated 
with either inflammation or disease activity (90-92). With regard to protein damage, 
the protein carbonyl content was increased in colonic biopsies from both UC and CD 
patients (93). Also, the levels of and the balance between the most important 
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antioxidants were seriously impaired within inflamed intestinal mucosa of IBD 
patients compared with normal mucosa (94; 95). 
Role of iron 
When iron meets the inflamed intestinal mucosa it may promote the production of 
OH• and thereby aggravate tissue damage. Both haeme from chronic mucosal 
bleeding and dietary iron are sources of redox active iron (96). Most of ingested iron 
is not taken up, but passed on with the faecal stream. The bulk of inorganic iron is 
stabilised in iron hydroxide polymers (97; 98). However, a small but significant 
fraction of the total iron concentration in faeces exists as low molecular chelated iron 
(99). Bile pigments and amino acids are potential chelators within the intestinal tract 
(77). Furthermore, low dose oral ferrous sulphate supplementation markedly 
increased the concentration of weakly chelated iron in faeces (99).  
The oxidative potential of i.v. iron compounds is considerably less than that of 
ferrous salts. Also, i.v. administration does not favour intestinal iron accumulation.  
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2. Aims of the study 
The overall objective of the present study was to investigate the effects of iron 
therapy on markers of oxidative stress and clinical disease activity in IBD. 
The specific aims of the four papers included in the thesis were: 
I To compare plasma antioxidant status in patients with CD with that of healthy 
controls, and to see if oral intake of ferrous fumarate changed plasma 
antioxidant status. In addition, to evaluate the effects of ferrous iron therapy on 
disease activity, and to evaluate iron absorption in patients with CD and iron 
deficiency.  
II To evaluate the effects of low-dose oral ferrous fumarate given by gavage on 
intestinal inflammation and plasma redox status in DSS-induced colitis in 
Wistar rats.  
III To evaluate the effects of oral ferrous fumarate and intravenous iron sucrose 
on clinical disease activity and plasma redox status, and to compare the two 
treatment modalities in patients with CD or UC, and iron deficiency anaemia.  
IV To compare the effects of oral ferrous sulphate and oral iron-polymaltose 
complex on markers of oxidative tissue damage and clinical disease activity in 
patients with CD or UC, and iron deficiency. 
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3. Materials and methods 
An overview of study designs, experimental groups, inclusion criteria, interventions 
and measurements are given in Table II and Table III. Details are outlined or refereed 
in the papers. Only a few issues need to be commented here. 
Table II. Overview of study designs, experimental groups, inclusion criteria, and interventions. 
 Study design Experimental groups Inclusion criteria Interventions 
 
Study I 
 
Prospective,      
case-control 
 
10 CD patients 
10 healthy controls 
 
Iron deficiency 
 
Ferrous fumarate 
tabs 120 mg/day for 
7 days 
Study II Factorial design 40 Wistar rats: 
Control (8) 
Sham gavage (8) 
Iron (8) 
DSS (8) 
Iron + DSS (8) 
 Iron: Ferrous 
fumarate 0.60 
mgFe2+/kg/day  
days 1-14 
DSS: DSS 5% in 
drinking water    
days 8-14 
 
Study III Prospective, 
randomised,       
non-blinded, 
crossover 
11 CD patients 
8 UC patients 
Iron deficiency 
anaemia: 
Hb < 12 g/dL in 
females 
Hb < 13 g/dL in 
males 
and 
Ferritin < 50 µg/L 
 
Ferrous fumarate 
tabs 120 mg/day for 
14 days 
and 
Iron sucrose 200 mg 
i.v. 3 times during   
14 days 
Study IV Prospective, 
randomised,       
non-blinded,       
with 2 parallel 
treatment groups 
24 CD patients 
17 UC patients 
Iron deficiency: 
MCV < 80 fL 
or 
Ferritin < 15 µg/L 
or 
Soluble transferrin 
receptor > 1.54 
mg/L 
Ferrous sulphate 
tabs 100 mg twice 
daily for 14 days 
or 
Iron polymaltose 
complex tabs 200 
mg once daily for  
14 days 
 
Abbreviations: DSS = dextran sulfate sodium; Hb = haemoglobin; MCV = mean corpuscular volume 
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Table III. Overview of measurements. In study I, III, and IV measurements were carried out before and 
after intervention. In study III, measurements were carried out at sacrifice of the rats. 
 Clinical disease activity Blood samples Urine samples Faecal samples Histology 
 
Study I 
 
CDAI for CD 
CDAI diary for all 
 
Routine lab. inv. 
Iron absorption 
Aminothiols 
Vitamin C, E 
Beta-carotene 
   
Study II  Plasma iron 
MDA 
Aminothiols 
Vitamin A, C, E 
 GMP Crypt and 
inflammation 
scores 
Study III HBSI for CD 
SCCAI for UC 
CDAI diary for all 
Routine lab. inv. 
MDA 
Aminothiols 
Vitamin A, C, E 
Beta-carotene 
 Calprotectin  
Study IV HBSI for CD 
SCCAI for UC 
CDAI diary for all 
Routine lab. inv. 
MDA 
Aminothiols 
Vitamin A, C, E 
Beta-carotene 
8-iso PGF2α Calprotectin  
Abbreviations: CDAI = Crohn’s Disease Activity Index; HBSI = Harvey-Bradshaw Simple Index of 
Crohn’s Disease Activity; SCCAI = Simple Clinical Colitis Activity Index; Routine lab. inv. = routine 
laboratory investigations; MDA = malondialdehyde; 8-iso PGF2α = Urine 8-isoprogstaglandin F2α;  
GMP = granulocyte marker protein 
  
3.1 Experimental groups 
Patients were recruited from the outpatient clinics at Haukeland University Hospital 
(study I, III, and IV), Førde County Hospital (study III), Haugesund Hospital (study 
III), Stord Hospital (study III), and Stavanger University Hospital (study IV). In study 
I, healthy controls were recruited from medical students and staff at Haukeland 
University Hospital. 
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3.2 Clinical disease activity 
In paper I, clinical disease activity was evaluated according to Crohn’s Disease 
Activity Index (CDAI) (100). Scores of > 150 indicate active CD. CDAI has no upper 
limit. 
In paper III and IV, the Harvey-Bradshaw Simple Index of Crohn’s Disease Activity 
(101) was applied for patients with CD, and the Simple Clinical Colitis Activity 
Index (102) was applied for patients with UC. These indices were used because they 
are similar regarding design and clinical significance of a given change in score. For 
the Harvey-Bradshaw Simple Index, maximum score is 25 and scores of ≥ 5 indicate 
active CD. For the Simple Clinical Colitis Activity Index maximum score is 20 and 
scores of ≥ 4 indicate active UC. To allow pooling of results from patients with CD 
and UC, disease activity scores were calculated as actual score divided by maximum 
score. 
3.3 Laboratory investigations 
In paper I, plasma levels of the total, reduced and oxidised forms of aminothiols 
(glutathione, cysteine, cysteinyl-glycine and homocysteine) were measured. To 
determine the reduced and oxidised forms, a derivatising agent was added to the 
vacutainer tubes before blood sapling. This was done with an insulin syringe with a 
very thin needle. 
In paper III and IV, plasma levels of the reduced and oxidised forms were not given. 
When conducting these studies, the insulin syringes were no longer available, and we 
had to use somewhat thicker needles to inject the derivatising agents into the 
vacutainer tubes. This often resulted in loss of vacuum in the tubes, and hence the 
tubes were filled with a variable volume of blood during sampling. Also, between 
study I and III/IV, the Laboratory of Clinical Biochemistry at Haukeland University 
Hospital changed from tubes with liquid additives to tubes with dry additives. We 
often observed that the tubes with dry additives were incompletely filled during 
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sampling. Since the volume of derivatising agents added was constant, but the 
volume of blood drawn was highly variable, the dilution of the blood varied. As a 
consequence, the results of the analyses of the reduced and oxidised forms of 
aminothiols in study III and IV were incoherent. 
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4. Summary of results 
4.1 Paper I 
Ferrous fumarate deteriorated plasma antioxidant status in patients with 
Crohn disease 
At inclusion, plasma reduced cysteine was lower (p=0.038) in patients compared with 
controls. One week of ferrous iron supplementation further decreased reduced 
cysteine (p<0.001) and decreased plasma reduced glutathione (p=0.004) in the 
patients. Following one week of ferrous fumarate supplementation the CDAI tended 
to increase (p=0.071). Patients, but not controls, experienced more diarrhoea, 
abdominal pain and nausea.  Serum iron increased significantly in patients (from 
5.8±3.2 to 30.9±13.1 µmol/L) and controls (from 18.4±8.0 to 34.5±12.5 µmol/L) 
after an oral iron load test. Variation in iron absorption was large among patients. 
4.2 Paper II 
Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats 
with DSS-induced colitis 
DSS significantly increased histological colitis scores (p<0.001) and faecal GMP 
(p<0.01). Ferrous fumarate further increased histological colitis scores (p<0.01) in 
DSS induced colitis. DSS + ferrous fumarate decreased plasma vitamin A as 
compared with controls (p<0.01). Otherwise, no changes were seen in plasma MDA, 
plasma antioxidant vitamins or plasma aminothiols. 
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4.3 Paper III 
Oral ferrous fumarate or intravenous iron sucrose for patients with 
inflammatory bowel disease 
Following oral ferrous fumarate clinical disease activity (p=0.037), general well 
being score (i.e. patients felt worse) (p=0.027) and abdominal pain score (p=0.027) 
increased, while no changes were seen following iron sucrose. CRP and faecal 
calprotectin were unchanged after both treatments. As compared with iron sucrose, 
ferrous fumarate increased CDAI scores of general well being (p=0.049), while 
changes in clinical disease activity (p=0.14) and abdominal pain score (p=0.20) did 
not differ. Ferrous fumarate did not significantly alter plasma MDA or plasma 
antioxidants. Iron sucrose increased plasma MDA (p=0.004) and decreased plasma 
vitamin C (p=0.017) and beta-carotene (p=0.008). Changes in plasma parameters did 
not differ significantly between treatments. 
4.4 Paper IV 
Effects of ferrous sulphate and non-ionic iron-polymaltose complex on 
markers of oxidative tissue damage in patients with inflammatory bowel 
disease 
Following ferrous sulphate plasma malondialdehyde (MDA) increased (p=0.02), 
while urine 8-isoprostaglandin F2α (8-iso-PGF2α) and plasma antioxidants did not 
change significantly. Iron-polymaltose complex did not change plasma MDA, urine 
8-iso-PGF2α or plasma antioxidants. Comparing the two treatments, changes in 
plasma MDA tended to differ (p=0.08), while urine 8-iso-PGF2α and plasma 
antioxidants did not differ. Neither ferrous sulphate nor iron-polymaltose complex 
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altered clinical disease activity indices and alterations in stool frequency, abdominal 
pain and nausea did not differ between treatments. 
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5. General discussion 
5.1 Oxidative stress 
Tissue damage due to oxidative stress is considered important in the pathogenesis of 
IBD (89). It was hypothesised that oral ferrous iron therapy would enhance intestinal 
inflammation by catalysing production of ROS. In our first study we found 
significantly lower plasma levels of reduced cysteine and beta-carotene in patients 
compared with controls. Following one week of ferrous fumarate therapy plasma 
levels of reduced cysteine and reduced glutathione decreased in patients, but not in 
controls. These findings were discussed in an editorial by C. Gasche (103), and 
commented in a letter to the Editor by P. Nielsen (104) which again was commented 
by the author (105). These publications are enclosed after paper I. In study III, we 
found no significant change in plasma redox status of IBD patients following ferrous 
fumarate 120 mg/day for two weeks. However, in study IV, plasma MDA increased 
and urine 8-iso PGF2α tended to increase after two weeks of ferrous sulphate 200 
mg/day for two weeks, indicating increased lipid peroxidation. Significant changes in 
plasma MDA in study IV but not in study III may be due to higher ferrous iron 
dosage in study IV. No changes in plasma redox status were found following iron-
polymaltose complex treatment. To our knowledge, there are no other publications 
regarding oral iron therapy and oxidative stress in patients with IBD. 
In study II, low-dose oral ferrous fumarate was given by gavage to Wistar rats with 
DSS-induced colitis. Ferrous fumarate increased histologic colitis scores in rats with 
colitis. Plasma antioxidant status, however, remained largely unchanged. 
Administration by gavage allowed exact iron dosage. The ferrous fumarate dose 
given was 0.60 mg Fe2+/kg/day. In humans, normal iron content in the diet is 0.15-
0.20 mg Fe2+/kg/day, and standard iron replacement therapy is 2-3 mg Fe2+/kg/day.  
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Lately, several studies of experimental colitis in rats have demonstrated increased 
intestinal inflammation as assessed by histology following iron fortification of the 
diet (106-109). In these studies, the diet was enriched with iron salts in the order of 
10 to 100 times the normal iron content. In DSS-induced colitis in mice, twofold, 
fivefold, and 10-fold iron enriched diets increased the severity of colitis in a nearly 
dose-dependent manner (110). Increased intestinal inflammation was associated with 
increased colonic (106; 108; 109) and plasma lipid peroxidation products (107) and 
decreased plasma antioxidant vitamins (106), consistent with increased oxidative 
stress. Furthermore, in a long term carcinogenesis experiment in DSS-induced colitis 
in mice, a two-fold iron-enriched diet significantly increased colorectal tumor 
incidence as compared with animals fed on a control diet (110). 
Control animals on iron supplementation had normal colonic histology in our study, 
and in all the cited studies. It seems therefore that pre-existing inflammation is 
necessary for visible damage to occur within these dose ranges.  
Taken together, present evidence suggests that caution should be exercised in the use 
of oral ferrous iron therapy to IBD patients. Haeme iron formulations are probably 
not safer alternatives, because haeme bound iron is redox active (111). Iron-
polymaltose may be an alternative for oral iron administration. Iron-polymaltose 
complex has a high complex stability, and a significant increase in the concentration 
of weakly bound iron in faeces is therefore not likely to occur following oral intake. 
However, evidence regarding safety and efficacy of iron-polymaltose complex in 
IBD patients is still inadequate.  
In study III, treatments with i.v. iron sucrose and oral ferrous fumarate to patients 
with CD and UC were compared with regard to plasma redox status. Following iron 
sucrose therapy plasma MDA increased, and plasma vitamin C and plasma beta-
carotene decreased, indicating increase in oxidative stress. After ferrous fumarate 
therapy changes were not significant. Clinically, this study is relevant because these 
are the ways we treat the patients. Scientifically, however, it is quite unfair. Iron 
sucrose in a rather high dose was administered i.v., which is in the same compartment 
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as redox status was measured. It is likely that i.v. administered iron exerts its 
catalytical properties mainly in the intravascular compartment. Following oral iron 
administration it is the intestinal mucosa that is heavily exposed to the iron load. 
Apparently, changes in redox status in the gastrointestinal tract have to be substantial 
to be recognised in plasma, while intravascular changes are more readily recognised. 
No i.v. iron compounds generate detectable free iron after infusion (112). However, 
all i.v. iron agents show evidence of a labile, biologically active iron fraction (112). 
The rate of labile iron release is estimated to 2-6% of total iron and follows the 
sequence iron dextran < iron sucrose < iron gluconate (59; 113; 114). Transferrin 
scavenges most of this labile iron (114), but some is bound to serum albumin, citrate, 
and other negatively charged ligands (115). This non-transferrin-bound iron (NTBI) 
has the potency to become redox active (98). The extent of NTBI following iron 
infusion is likely to be dose dependent (113; 116). Labile iron release may be 
responsible for the reactions seen when giving too much of any i.v. iron agent too fast 
(112). 
In patients with chronic renal failure, increased plasma levels of MDA was found 
following infusions of 100 mg iron sucrose (116-118) and 125 mg iron gluconate 
(119). Increase in MDA was significantly related to NTBI (116). Also, infusion of 
100 mg iron sucrose to healthy volunteers increased oxygen radical formation 
assessed by whole-blood electron spin resonance (120). The acute effects of i.v. iron 
are believed to be modest and transient, but chronic, repeated administration may 
produce longer lasting pro-oxidant effects (121).  
The long term significance of increased oxidative stress after i.v. iron is currently 
unknown. In IBD, concerns are mainly related to the possibility of i.v. iron to 
influence intestinal inflammation. However, it was recently shown that systemic 
(intraperitoneal) administration of iron dextran in a moderately high dose did not 
exacerbate intestinal inflammation or increase colorectal tumor incidence in 
experimental colitis in mice (122). In chronic renal failure, oxidative stress is 
proposed to contribute to the increased risk of cardiovascular disease (118; 123). 
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Still, there is little evidence that i.v. iron adversely affects survival in patients with 
dialysis dependent chronic renal failure (121). Besides, anaemia itself increases 
oxidative stress, whereas increasing haemoglobin levels to > 11 g/dL reduces 
oxidative stress (124). To date, the benefits of improving anaemia with intravenous 
iron are thought to outweigh the potential for long term iron toxicity (124).   
Most studies conclude that higher doses of i.v. iron yield better results in term of 
efficacy (63). However, even if unproven, the potential for exacerbation of oxidative 
stress-related disease give rise to safety concerns regarding the administration of high 
doses. Until we have more information, it therefore seems prudent to avoid frequent 
high-dose iron infusions.  
The goal of i.v. iron therapy in IBD associated anaemia is to provide sufficient iron to 
support maximal erythropoiesis, but to avoid iron excess. In normal circumstances, 
about 20-25 mg iron per day is required to support the haemoglobinisation of new 
erythrocytes. In anaemia and erythropoietin therapy, the erythropoietic activity is 
increased. A large portion of the required iron comes from red cell destruction even 
in anaemia, and the amount of supplemented i.v. iron required is probably between 
100 and 200 mg per week. Depending of the degree of anaemia, single infusions of 
200 mg iron sucrose can be given once weekly or every second week until target 
haemoglobin is reached. 
We measured plasma (study I-IV) and urine (study IV) parameters as markers of 
oxidative stress. These are not ideal for estimation of oxidative stress in the 
gastrointestinal tract of IBD patients. Measurements in colonic biopsies would 
possibly be more sensitive. However, multiple biopsies are needed. In the animal 
models of IBD, 8-16 biopsies per colon were necessary to reveal the deleterious 
effects of iron on histologic colitis changes (125; 126), while 100 mg of colonic 
tissue was used to measure lipid peroxidation products (109). Furthermore, rectal 
biopsies may be inadequate for evaluation of oxidative tissue damage following oral 
iron therapy. The faeces passes through rectum during defecation, otherwise the 
rectum is practically empty. Consequently, contact time between faecal iron and the 
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rectal mucosa is short. Faecal transit time is longer in the colon, increasing the 
probability of faecal iron to catalyse production of ROS. Therefore, flexible 
sigmoidoscopy or full colonoscopy with multiple biopsies, before and after iron 
therapy, is necessary for an optimal evaluation. In clinical practise this would take a 
lot of resources and make recruitment of patients more difficult. 
Faecal bacteria may also be involved in oral iron toxicity. The intestinal flora is 
thought to play a pathogenic role in human IBD (1) as well as in experimental colitis 
(127). Oral iron supplementation could exacerbate intestinal inflammation by altering 
the microbial balance in an unfavourable manner. In line with this, ferrous sulphate 
supplementation in rats led to strong alterations in faecal flora such as to favour the 
growth of microorganisms with a pathogenic potential (128). Besides, the respiratory 
activity of faecal bacteria is a ready biologic source of ROS (77). 
5.2 Clinical disease activity 
In study I and III, IBD patients given oral ferrous fumarate therapy experienced 
increase in clinical disease activity and symptoms like abdominal pain, nausea and 
diarrhoea. Side-effects were more pronounced in CD patients compared with healthy 
controls. In study IV, an enteric coated ferrous sulphate compound had less impact on 
clinical disease activity and abdominal pain and nausea. Better tolerance may be 
related to the slow-release formulation or to low disease activity in the patients 
studied. There was no difference in tolerance when comparing ferrous sulphate and 
iron-polymaltose complex. However, three of 21 patients discontinued ferrous 
sulphate, while one of 19 patients discontinued iron-polymaltose complex, due to 
gastrointestinal side-effects. 
It is believed that at least the upper the gastrointestinal side-effects seen with ferrous 
salts are related to oxidation with formation of ROS within the lumen of the gut 
(129). Furthermore, iron induced alterations in the microbial balance may possibly 
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cause gastrointestinal discomfort, especially in patients with small intestinal bacterial 
overgrowth. 
In study I and IV, IBD patients taking ferrous iron tablets experienced increased stool 
frequency. Healthy controls experienced decreased stool frequency. The reason for 
changes in stool frequency is unknown. 
In study III, iron sucrose infusions were well tolerated, and had no influence on 
clinical disease activity or specific gastrointestinal symptoms in IBD patients. When 
comparing iron sucrose and ferrous fumarate, alterations (from before to after 
treatment) in clinical disease activity did not reach statistical significance. However, 
all the patients completed iron sucrose treatment, while two patients discontinued 
ferrous fumarate treatment due to side-effects. Incorrectly, this distinction was not 
taken into account in the statistical calculations, as the two non-compliant patients 
were excluded from the analyses. Including these patients in the statistics by 
assigning post-treatment disease activity and symptom scores as described in paper 
IV, alterations in clinical disease activity (p=0.04) and general well-being (p=0.03) 
differed significantly, and alterations in abdominal pain (p=0.05) tended to differ. 
5.3 Iron absorption 
In study I, iron absorption was evaluated by an oral iron load test. CD patients with 
iron deficiency anaemia had increased iron absorption compared with healthy 
controls with normal iron status. However, there was larger variation in iron 
absorption among patients than controls, especially after 1 week of ferrous fumarate 
therapy. A few patients with CD located in the ileum and colon had little serum iron 
increase 2 hours after iron administration. These patients had clinically active disease 
with CDAI values between 200 and 300 at inclusion, and decreased intestinal iron 
absorption may therefore reflect anaemia of chronic disease. Iron absorption can 
occasionally be impaired in extensive CD of the duodenum and upper jejunum (14). 
 45
However, anaemia of chronic disease is probably a more common reason for 
decreased iron absorption in IBD. 
 46 
6. Conclusions 
The main conclusions of the present study are as follows: 
1. Oral ferrous iron therapy increased oxidative stress in patients with IBD. 
Oxidative changes are believed to occur primarily in areas of inflamed 
intestinal mucosa and may aggravate intestinal inflammation. 
2. Oral iron-polymaltose complex therapy did not affect plasma redox status in 
patients with IBD. 
3. Low-dose oral ferrous fumarate therapy increased intestinal inflammation in 
DSS-induced colitis in rats.  
4. I.v. iron sucrose therapy increased oxidative stress in patients with IBD. This 
oxidative stress is believed to occur in the intravascular department, to be dose 
dependent and transient. Its long term significance is currently unknown. 
5. Side-effects of oral ferrous fumarate therapy were more pronounced in CD 
patients compared with healthy controls. IBD patients given ferrous fumarate 
experienced increase in clinical disease activity and gastrointestinal symptoms. 
Enteric coated ferrous sulphate tablets and iron-polymaltose complex tablets 
had less impact on disease activity and symptoms. There was no difference in 
tolerability of ferrous sulphate and iron-polymaltose complex.  
6. I.v. iron sucrose therapy was well tolerated, and had no influence on clinical 
disease activity scores or gastrointestinal symptoms in IBD patients. Iron 
sucrose showed better tolerance as compared with oral ferrous fumarate. 
7. CD patients absorb iron. However, iron absorption may be decreased due to 
anaemia of chronic disease. 
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7. Clinical implications 
In consequence of the evidences recently discussed we propose a modified algorithm 
for the treatment of IBD associated anaemia (Figure 2). The main differences from 
the algorithm given by Gasche et al. (Figure 1) are the lower i.v. iron sucrose dose, 
and the omission of oral ferrous iron in the treatment of latent iron deficiency.  
Hb 10.0 - 12.0 g/dL in female
Hb 10.0 - 13.0 g/dL in male
Ferritin < 200 µg/L
Hb > 12.0 g/dL in female
Hb > 13.0 g/dL in male
Ferritin < 20 µg/L
Hb < 10 g/dL
Transferrin > 2.9 g/L
Hb < 10 g/dL
Transferrin < 2.9 g/L
Iron sucrose
200-300 mg/wk
Erythropoietin
150 U/kg, 3 x per wk  
Iron sucrose
200 mg/wk
If Hb increase is < 2 g/dL
after 4 weeks
add erythropoietin
Iron sucrose
200 mg/ 2 wks
Iron sucrose 200 mg x 2
or
Oral iron-polymaltose
100 mg/day
Target Hb
12.0 g/dL in female
13.0 g/dL in male
 
Figure 2 Algorithm for the treatment of IBD associated anaemia.  
Complete blood count, iron status, vitamin B12 and folic acid must be checked before 
start of iron therapy. Intestinal inflammation should be actively treated to reduce 
blood loss and to alleviate anaemia of chronic disease. It is recommended that iron 
therapy is stopped in patients with ongoing infection (e.g. bacteraemia or abscess) or 
at transferrin saturation > 50% (8; 63). 
Depending on the degree of anaemia, 200 mg iron can be given every week or every 
second week. Iron sucrose can be given as single doses of 100 or 200 mg, diluted in 
100 mL saline 0.9%. Recommended speed of infusion is 30 min/100 mg iron sucrose. 
The total amount of iron needed to correct anaemia can be estimated using the 
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approximation that 200 mg of i.v. iron is required for a haemoglobin increase of 1 
g/dL. Moreover, another 500 mg of iron should be given to replenish the iron stores. 
Alternatively, the total iron dose to be administered can be calculated from the 
formula: Total iron deficit (mg) = body weight (kg) ∗ 2.4 ∗ (target haemoglobin 
(g/dL) − actual haemoglobin (g/dL)) + 500 mg (40). In cases of ongoing blood loss 
the total amount of iron needed may be increased. 
Transferrin levels below 2.9 g/L (equivalent to TIBC of 73 µmol/L), soluble 
transferrin receptor below 50 nmol/L (equivalent to 2.7 mg/L), or erythropoietin 
below 100 U/L indicated resistance to iron sucrose in IBD patients with haemoglobin 
≤ 10.5 g/dL (42). These parameters may help to identify patients who benefit from 
additional erythropoietin treatment. The number of weeks proposed for iron sucrose 
therapy alone before adding erythropoietin should be complied with judgement. In 
patients with ongoing blood loss, treatment with iron sucrose alone should be 
extended. Patients with active IBD, anaemia with haemoglobin > 10 g/dL and a 
moderate response to i.v. iron therapy may also gain profit by combination therapy 
with erythropoietin.  
Treatment of latent iron deficiency, iron stores are empty but anaemia has not yet 
developed, is a matter of discussion. If the patient does not have any complaints 
attributed to iron deficiency the situation can be awaited. Alternatively, i.v. iron 
sucrose may be administered twice, or oral iron-polymaltose may be given for several 
weeks. Iron-polymaltose is currently not available in Scandinavia, but may be 
imported with exemption from registration given by national medicines authorities. 
However, data regarding safety and efficacy of iron-polymaltose in IBD patients is 
still inadequate. 
Haemoglobin and iron status (serum iron, TIBC, ferritin) should be assessed regularly 
during after iron therapy. Percent transferrin saturation is derived from dividing the 
serum iron into the TIBC and multiplying by 100. Because i.v. iron compounds 
interfere with clinical laboratory determination of serum iron, blood samples should 
be taken before or 2 days after an iron sucrose infusion (60). Serum ferritin levels 
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may not accurately reflect iron stores for a period of up to 1 week after i.v. iron 
therapy (63). 
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